Longitudinal Observation of Brain Ischemia and Blood Brain Barrier Permeability in the Acute Phase of Ischemic Stroke
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cerebral Stroke
- Sponsor
- Charite University, Berlin, Germany
- Enrollment
- 410
- Locations
- 1
- Primary Endpoint
- clinical outcome measured with the modified Rankin Scale (mRS)
- Last Updated
- 12 years ago
Overview
Brief Summary
The objective of this trial is to visualize blood brain barrier function and metabolic changes in the first days after ischemic stroke with new investigational MRI sequences.
Detailed Description
In this study the investigators will be examining acute ischemic stroke patients on the first and second day after symptom onset using repetitive MRI examinations to visualize blood brain barrier function and metabolic changes of the brain in 5 sub-projects, each containing a specific MRI protocol with one of the following new MRI sequences: 1. T1-Dynamics (measuring disruptions of the blood-brain barrier) 2. pH-imaging (measuring metabolic changes, acidosis) 3. Resting-state MRI (measuring changes in the cerebral perfusion) 4. Quantitative MRI-Angiography (quantification of blood flow in single vessels) 5. Diffusion Tensor Imaging (DTI) for patients with Anterior Choroidal Artery (AChA)-Infarcts (quantification of damage of white matter tracts) Each sub-projects will be conducted in blocks of a specific time span. Morphological outcome will be assessed at day 5-7. Clinical outcome will be assessed at day 5-7 and day 90. The association of the new imaging parameter with the clinical and morphological outcome measures will be analysed. No specific intervention is assigned to the subjects by the investigators of the study.
Investigators
Jochen B. Fiebach
MD
Charite University, Berlin, Germany
Eligibility Criteria
Inclusion Criteria
- •Suspected stroke or transient ischemic attack (TIA) within 24h from symptom onset
Exclusion Criteria
- •MRI contraindication, age \< 18 years, intracranial hemorrhages
Outcomes
Primary Outcomes
clinical outcome measured with the modified Rankin Scale (mRS)
Time Frame: on day 90
conducted as telephone interview
clinical outcome measured with the National Institutes of Health Stroke Scale (NIHSS)
Time Frame: on follow-up examination day 5-7
Secondary Outcomes
- final lesion volume (measured on FLAIR images)(on follow-up examination day 5-7)